At UAS we continually invest in gold-standard probiotic clinical research & trials for both single strains and finished formulations. We take pride in advancing the industry with scientific data and clinical research.
Our Chief Scientific Officer, Dr. Gregory Leyer, has dedicated his professional career to probiotic advancement. He has authorship in over 20 probiotic-related publications and is an active member of the International Probiotic Association (IPA) and International Scientific Association for Probiotics and Prebiotics (ISAPP).
Dr. Greg leads our in-house research teams as they apply their knowledge of ingredient combinations and clinical documentation to formulate probiotics that support desired structure-function claims. The team does not hesitate when it comes to investing in strains with promise. We will do what’s necessary to complete research and confirm the strain’s related health benefits.
Our team has completed extensive research on a number clinically-validated trademarked superstrains:
UAS Labs is proud to offer their latest exclusive offering, Lactobacillus plantarum PPLP-217™, which has been the focus of ground-breaking studies in neonates and young infants. UAS Labs has partnered with renowned pediatric infectious disease expert Pinaki Panigrahi MD, PhD, FIDSA, on future strain development and research. Together, they will establish PPLP-217™ as the go-to strain for supporting infant health* Learn More…